1. Home
  2. LIDR vs SCYX Comparison

LIDR vs SCYX Comparison

Compare LIDR & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AEye Inc.

LIDR

AEye Inc.

HOLD

Current Price

$1.82

Market Cap

69.8M

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.67

Market Cap

60.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LIDR
SCYX
Founded
2013
1999
Country
United States
United States
Employees
45
29
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.8M
60.4M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
LIDR
SCYX
Price
$1.82
$0.67
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$4.75
$3.00
AVG Volume (30 Days)
6.0M
338.4K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.36
EPS
N/A
N/A
Revenue
N/A
$257,000.00
Revenue This Year
$2,604.29
N/A
Revenue Next Year
$466.58
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.68
$0.57
52 Week High
$6.44
$1.29

Technical Indicators

Market Signals
Indicator
LIDR
SCYX
Relative Strength Index (RSI) 45.41 31.84
Support Level $1.80 $0.69
Resistance Level $2.75 $0.70
Average True Range (ATR) 0.15 0.06
MACD -0.04 -0.03
Stochastic Oscillator 8.08 15.56

Price Performance

Historical Comparison
LIDR
SCYX

About LIDR AEye Inc.

AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: